TCI Wealth Advisors’s Arcturus Therapeutics ARCT Stock Holding History
Bought
Maintained
Sold
Other funds holding ARCT
AIM
NAMA
TCI Wealth Advisors's ARCT Position: Q1 2022 in Review
TCI Wealth Advisors sold out of Arcturus Therapeutics (ARCT) in Q1 2022, closing a stake of 65 shares — an estimated $2K sold.
TCI Wealth Advisors first reported a position in ARCT in Q1 2021 and held it in 4 quarters. The position peaked at $3K in Q3 2021. 130 funds tracked by Wall St. Rank hold ARCT as of Q1 2022.
- TCI Wealth Advisors reported no remaining Arcturus Therapeutics position as of Q1 2022 after selling out during the quarter.
- TCI Wealth Advisors sold 65 Arcturus Therapeutics shares in Q1 2022, an estimated $2K.
- TCI Wealth Advisors first reported a position in Arcturus Therapeutics in Q1 2021 and held it in 4 quarters.
- TCI Wealth Advisors's Arcturus Therapeutics position peaked at $3K in Q3 2021.
- 130 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2022.
Based on TCI Wealth Advisors's 13F filing for Q1 2022, filed 29 Apr 2022.